A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma.

Erel Joffe,Santosha Adipudi Vardhana,Anita Kumar,Mehrdad Abedi,Rasmus T. Hoeg,Elad Sharon,Anas Younes

A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma.

2020

Erel Joffe
Santosha Adipudi Vardhana
Anita Kumar
Mehrdad Abedi
Rasmus T. Hoeg
Elad Sharon
Anas Younes

TPS8072Background: Diffuse large B-cell lymphoma (DLBCL) escapes host immune responses via inhibition of the B2M and CD58 pathways and upregulation of PD-1 ligands. However, treatment results with ...

Keywords:

Mogamulizumab
Pathology
Pembrolizumab
Refractory Diffuse Large B-Cell Lymphoma
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations